Late gastrointestinal and urogenital side-effects after radiotherapy – Incidence and prevalence. Subgroup-analysis within the prospective Austrian–German phase II multicenter trial for localized prostate cancer

Schmid, Maximilian; Pötter, Richard; Bombosch, Valentin; Sljivic, Samir; Kirisits, Christian; Dörr, Wolfgang; Goldner, Gregor

doi:10.1016/j.radonc.2012.05.007

Cited by 41 publications

(34 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The treatment-related urinary symptoms also show significant levels of reversibility [25,26]. Given the circumstances surrounding the urinary symptoms, the use of cumulative or actuarial incidence alone may misrepresent and overestimate the actual burden [25,26]. Thus, the current study used the prevalence at specific time points in addition to the peak incidence.…”

Section: Discussionmentioning

confidence: 99%

“…2. The reversibility of treatment-related urinary symptoms plays an important role [25,26]. The improvements due to the natural healing process or successful management may introduce fluctuation of association at different time points.…”

Section: Discussionmentioning

confidence: 99%

“…The median follow-up of 72 months is available. Schmid et al demonstrates that the majority of urinary symptoms following EBRT are transient [25]. Reporting the incidence rate alone may overestimate the actual symptom burden and may have higher level of cumulative noise [25,26], thus, both prevalence and incidence are reported in the current analysis.…”

Section: Symptom Prevalence and Incidencementioning

confidence: 97%

“…Schmid et al demonstrates that the majority of urinary symptoms following EBRT are transient [25]. Reporting the incidence rate alone may overestimate the actual symptom burden and may have higher level of cumulative noise [25,26], thus, both prevalence and incidence are reported in the current analysis. The symptom prevalence at the end of radiotherapy treatment represents the acute symptoms while the prevalence at 18-, 36-and 54-month post randomisation followups represent the late symptoms.…”

Section: Symptom Prevalence and Incidencementioning

confidence: 97%

See 3 more Smart Citations

Dosimetry, clinical factors and medication intake influencing urinary symptoms after prostate radiotherapy: An analysis of data from the RADAR prostate radiotherapy trial

Yahya

Ebert

Bulsara

et al. 2015

Radiotherapy and Oncology

View full text Add to dashboard Cite

Urinary symptoms (frequency, incontinence, dysuria and haematuria) were prospectively assessed using LENT-SOMA to a median of 72 months. The endpoints assessed were prevalence (grade≥1) at the end of radiotherapy (representing acute symptoms), at 18-, 36-and 54-month follow-ups (representing late symptoms) and peak late incidence including only grade≥2. Impact of factors were assessed using multivariate logistic regression models with correction for over-optimism. Results: Baseline symptoms, non-insulin dependent diabetes mellitus, age and PC1 (correlated to the mean dose) impact symptoms at >1 timepoints. Associations at a single timepoint were found for cerebrovascular condition, ECOG status and non-steroidal anti-inflammatory drug intake. Peak incidence analysis shows the impact of baseline, bowel and cerebrovascular condition and smoking status. Conclusions:The prevalence and incidence analysis provide a complementary view for urinary symptom prediction. Sustained impacts across time points were found for several factors while some associations were not repeated at different time points suggesting poorer or transient impact.4

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Symptom Prevalence and Incidencementioning

confidence: 97%

Section: Symptom Prevalence and Incidencementioning

confidence: 97%

See 2 more Smart Citations

Dosimetry, clinical factors and medication intake influencing urinary symptoms after prostate radiotherapy: An analysis of data from the RADAR prostate radiotherapy trial

Yahya

Ebert

Bulsara

et al. 2015

Radiotherapy and Oncology

View full text Add to dashboard Cite

show abstract

“…The same group reported on 178 primary prostate cancer patients treated within an Austrian-German multicenter trial by three-dimensional radiotherapy up to a local dose of 70 Gy or 74 Gy using an erB. After a median follow-up of 74 months the 5-year actuarial incidence rates for GI/GU grade C2 side effects were 19 and 23 % (Schmid et al 2012). …”

Section: Impact On Rectal Toxicitymentioning

confidence: 99%